Ads
related to: prostate cancer clinical trials 2023 schedule release- Mechanism of Action
Gain a Deeper Understanding of
How XTANDI® Is Thought to Work
- Treatment Guidelines
Review NCCN and AUA Guidelines That
Support the Use of XTANDI®.
- XTANDI® EMBARK Data
Review Xtandi EMBARK Trial Data and
Results.
- Mechanism of Disease
Disease Information & Implications
Of Treatment with XTANDI®
- Mechanism of Action
perfectfaqs.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Flotufolastat (18 F), sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. [1] The active ingredient is flotufolastat (18 F). [1] Flotufolastat (18 F) was approved for medical use in the United States in May 2023. [1] [2]
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.
The trial investigates new approaches for men with metastatic and locally advanced prostate cancer. [1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial. [2] The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall ...
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
[1] [2] [3] It is specifically comparing three to four 100 μg/day estradiol patches (FemSeven or Progynova TS) against goserelin implants in approximately 2,200 men with prostate cancer. [1] [4] The study was started in March 2006 and is estimated for completion in August 2021, with additional reports expected in 2023 and 2024.
Evofosfamide (INN, [1] USAN; [2] formerly known as TH-302) is a compound being evaluated in clinical trials for the treatment of multiple tumor types as a monotherapy and in combination with chemotherapeutic agents and other targeted cancer drugs.
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Ads
related to: prostate cancer clinical trials 2023 schedule releaseperfectfaqs.com has been visited by 100K+ users in the past month